Colorectal Cancer

Quick Answer

For colorectal cancer, FDG-PET/CT is most valuable in restaging — evaluating a rising CEA with negative conventional imaging, characterizing potentially resectable metastases (especially before hepatic metastasectomy), and assessing recurrence. Mucinous and signet-ring tumors are frequently FDG-low, so a normal SUV does not exclude them, and physiologic/inflammatory bowel uptake mimics tumor. (Esophageal and gastric cancers are covered on their own page.)

Definition

Colorectal cancer (CRC) is a malignant epithelial tumor — overwhelmingly adenocarcinoma — of the colon or rectum, most arising through the adenoma–carcinoma sequence from precursor polyps.

Synonyms

Colon cancer, rectal cancer, colorectal adenocarcinoma; mucinous and signet-ring-cell subtypes.

Epidemiology

CRC is among the most commonly diagnosed cancers and a major cause of cancer death; incidence in younger adults (< 50) has been rising, prompting earlier screening. Risk associates with older age, diet (red/processed meat, low fiber), obesity, smoking, alcohol, inflammatory bowel disease (ulcerative colitis > Crohn), and hereditary syndromes (Lynch, familial adenomatous polyposis).

Etiology & Risk Factors

• Age, diet/obesity/smoking/alcohol, and IBD.
• Hereditary: Lynch (dMMR) and FAP (APC); personal/family polyp history.

Pathophysiology

Most CRC follows the adenoma–carcinoma sequence: stepwise accumulation of mutations (APC → KRAS → TP53) with chromosomal instability. A parallel serrated pathway (BRAF mutation, CpG-island methylation, microsatellite instability) accounts for a minority with distinct biology. Lynch syndrome (germline mismatch-repair defect) produces MSI-high tumors with high mutational burden — the basis for immunotherapy sensitivity.

Genetics & Molecular Biology

• APC (Wnt), KRAS/NRAS (predict anti-EGFR resistance), BRAF V600E (poor prognosis, right-sided, serrated), TP53, SMAD4.
• MSI-high / dMMR — Lynch or sporadic (BRAF/CIMP); predicts immune-checkpoint benefit and better stage-for-stage prognosis in early disease.
• HER2 amplification — a therapeutic target in CRC.
• Sidedness (right vs left) carries prognostic and anti-EGFR-predictive weight.

Histopathology

Conventional adenocarcinoma (gland-forming), graded by differentiation. Mucinous (> 50% extracellular mucin) and signet-ring-cell carcinomas are distinct, often FDG-poor, and behave more aggressively. Precursor lesions: tubular/villous adenomas and sessile serrated lesions.

Clinical Presentation

Change in bowel habits, rectal bleeding / occult blood, iron-deficiency anemia (especially right-sided), obstruction, or asymptomatic screen-detected disease. Liver and lung are common metastatic sites; peritoneal spread is characteristic of signet-ring/mucinous tumors.

Laboratory Findings

• CEA — the key marker for surveillance and detecting recurrence; a rising CEA with negative conventional imaging is a prime FDG-PET indication.
• FIT / fecal occult blood and colonoscopy for screening/diagnosis.
• MMR/MSI testing on all CRC (Lynch screening + therapy); RAS/BRAF/HER2 for treatment selection.

Imaging Findings by Modality

• Colonoscopy: diagnosis and biopsy; CT colonography as an alternative screen.
• CT (chest/abdomen/pelvis): primary staging and burden; contrast liver phases for metastases.
• MRI: rectal local staging (T-stage, mesorectal fascia, EMVI) and liver metastasis characterization/count before metastasectomy.
• FDG-PET/CT: restaging, rising-CEA work-up, pre-metastasectomy detection of additional disease, and response assessment.

Radiopharmaceutical Uptake Mechanisms

FDG reflects glucose metabolism — high in typical adenocarcinoma but low in mucinous/signet-ring tumors (sparse viable cells in a mucin lake) and confounded by physiologic and inflammatory bowel uptake. FAPI targets stromal fibroblast activation protein and shows promise precisely in the desmoplastic, FDG-low, peritoneal disease where FDG struggles.

Typical PET Tracers

Typical SPECT Tracers

• No routine SPECT staging role; ⁹⁹ᵐTc-MAA mapping precedes ⁹⁰Y radioembolization of liver-dominant metastases (see that therapy page).

Therapy Indications

• Endoscopic/surgical resection; (neo)adjuvant chemotherapy (FOLFOX/CAPOX); rectal cancer neoadjuvant chemoradiation / total neoadjuvant therapy (with organ-preservation "watch-and-wait" in complete responders).
• Metastatic: chemotherapy ± anti-EGFR (RAS-wild-type, left-sided) or anti-VEGF; immunotherapy for MSI-high; HER2-directed therapy; hepatic metastasectomy for resectable liver-limited disease.
• Liver-directed: ⁹⁰Y radioembolization for liver-dominant, chemorefractory metastases.

Theranostics

The established GI theranostic here is ⁹⁰Y radioembolization for liver-dominant colorectal metastases — ⁹⁹ᵐTc-MAA mapping (lung-shunt/extrahepatic assessment) then intra-arterial ⁹⁰Y microspheres (SIRFLOX/FOXFIRE informed its role). FAPI-targeted imaging (and potentially therapy) is an emerging avenue for the FDG-low, stroma-rich, peritoneal phenotype.

Differential Diagnosis

• Physiologic/inflammatory bowel uptake, diverticulitis, and IBD flares mimic tumor on FDG-PET — correlate with CT and endoscopy.
• Adenoma (incidental focal colonic uptake — a high-yield actionable incidental warranting colonoscopy).
• Post-surgical/anastomotic inflammation and radiation change.

Reporting Checklist

• State the indication (restaging / rising CEA / pre-metastasectomy / response) and correlate with CEA trend.
• Localize recurrence (anastomotic, nodal, peritoneal, hepatic, pulmonary) and count/limit liver disease relevant to metastasectomy.
• Note the mucinous/signet-ring FDG-low caveat when SUV is unexpectedly low.
• Address bowel physiologic uptake and inflammatory mimics explicitly; flag incidental focal colonic uptake for colonoscopy.

Prognosis

Stage is the dominant driver (TNM). MSI-high early-stage disease has a favorable prognosis (and immunotherapy sensitivity if advanced); BRAF V600E and signet-ring/mucinous histology are adverse. Resection of liver-limited metastatic CRC can be curative in selected patients — the reason accurate pre-metastasectomy PET/CT matters.

Board facts at a glance

The tested essentials in one place:

Board Pearls

FDG-PET/CT's strongest colorectal indication is restaging — a rising CEA with negative/equivocal conventional imaging, and the pre-metastasectomy work-up, where finding additional (often extrahepatic) disease changes surgical candidacy. It also guides and follows ⁹⁰Y liver-directed therapy.

Mucinous and signet-ring tumors are frequently FDG-negative — never exclude disease on a normal SUV; and physiologic/inflammatory bowel uptake (diverticulitis) mimics tumor, so correlate with CT.

Incidental focal colonic FDG uptake is one of the two must-act incidentals (colonoscopy for a possible adenoma/carcinoma). Molecular testing is management-defining: RAS/BRAF predict anti-EGFR response, MSI-high/dMMR predicts immunotherapy benefit, and HER2 amplification is targetable.

Related Pages

• Disease: Esophageal & gastric cancer (the esophagogastric counterpart); Hepatocellular carcinoma.
• Therapy: ⁹⁰Y radioembolization (SIRT) for liver-dominant metastases; tracer: FDG, (emerging) FAPI.
• Pitfalls: Incidental findings on FDG-PET, Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• The adenoma–carcinoma vs serrated (BRAF/MSI) pathway diagram.
• A rising-CEA work-up algorithm ending at FDG-PET/CT.
• FDG vs FAPI side-by-side for mucinous/peritoneal disease.

Common Pitfalls

• Metformin causes intense diffuse bowel (especially colonic) FDG uptake that can obscure or mimic tumor — consider withholding it before scanning or use delayed/comparison imaging when the pattern is confounding.
• Recent chemotherapy transiently lowers FDG avidity, producing false negatives; respect an adequate post-treatment interval before calling response or excluding residual disease.
• Small-volume peritoneal carcinomatosis is under-detected (partial-volume effect), a limitation compounded when the histology is mucinous.
• Colostomy/ileostomy stoma sites show physiologic uptake that can be mistaken for peristomal recurrence — correlate with the stoma location on CT.

Self-Check (Board-Style)